AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

11.38-0.07 (-0.61%)

At close: 4:00PM EST

11.34 -0.04 (-0.35%)
After hours: 5:41PM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	11.45
Open	11.31
Bid	11.39 x 800
Ask	11.40 x 900
Day's Range	11.02 - 11.52
52 Week Range	9.76 - 23.50
Volume	987,613
Avg. Volume	546,253

Market Cap	471.711M
Beta (5Y Monthly)	1.40
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Business Wire
AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-04, the company’s investigational gene therapy for the treatment of cystinosis. AVR-RD-04 consists of the patient’s own hematopoietic stem cells, genetically modified to express cystinosin, the protein that is deficient in patients with cystinosis. AVR-RD-04 is currently being evaluated in a Phase 1/2 clinical trial (NCT03897361) sponsored by AVROBIO’s academic collaborator at the University of California, San Diego.1
- Better Buy: CRISPR vs. Fulgent Genetics
  Motley Fool
- SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Support Advancing a Novel Genome Engineering Platform for Non-Viral Gene Therapy
  GlobeNewswire
Business Wire
AVROBIO to Present at Three Upcoming Investor Conferences in March
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming virtual investor conferences.
- United Fire Group, Inc. to Participate in the 46th Annual AIFA Conference
  GlobeNewswire
- Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
  GlobeNewswire
Business Wire
AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a 100% reduction, or complete clearance, of toxic substrate in the kidney biopsy of the first patient dosed with the plato® gene therapy platform in the ongoing Phase 2 FAB-GTi clinical trial of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease. Kidney substrate reduction is the trial’s primary efficacy endpoint and has previously been used by the U.S. Food and Drug Administration (FDA) in evaluating and approving treatments for Fabry disease.